A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Panobinostat (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 14 Aug 2019 Planned initiation date changed from 1 Jun 2019 to 1 Oct 2019.
- 14 Aug 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 02 Aug 2019 Planned End Date changed from 1 Sep 2025 to 1 Oct 2025.